复方鳖甲软肝片联合恩替卡韦对慢性乙型肝炎肝纤维化患者的临床分析

Clinical Analysis of Compound Biejiaruangan Tablets Combined with Entecavir Efficacy on Patients with Hepatic Fibrosis of Chronic Hepatitis B

目的探讨复方鳖甲软肝片联合恩替卡韦对慢性乙型肝炎肝纤维化患者的疗效。方法方便选择2014年2月—2015年3月该院收治的慢性乙型肝炎肝纤维化患者64例。其中观察组32例采用复方鳖甲软肝片联合恩替卡韦治疗,对照组仅采用恩替卡韦治疗。比较两组患者治疗前后血清ALT、AST、透明质酸、粘连蛋白及Ⅲ型前胶原含量。结果治疗后,观察组血清ALT[(42.4±14.6)U/L vs(55.8±17.7)U/L]、AST[(34.3±12.2)U/L vs(43.2±13.5)U/L]、透明质酸[(95.6±28.6)ng/m L vs(128.2±25.7)ng/m L]、粘连蛋白[(102.6±21.4)ng/m L vs(125.3±24.6)ng/m L]均低于对照组,差异有统计学意义(P<0.05)。结论复方鳖甲软肝片联合恩替卡韦可有效改善慢性乙型肝炎肝纤维化患者的肝功能,降低肝纤维化相关细胞因子水平。

Objective To observe the curative effect of Fufangbiejiaruanganpian United en entecavir in patients with hepatic fibrosis of chronic hepatitis B. Methods Convenient selection 64 cases of chronic hepatitis B with hepatic fibrosis were selected from February 2014 to March 2015 in our hospital. The observation group of 32 cases with compound Biejiaruangan tablets combined with entecavir treatment, the control group only treated with entecavir.Compared with the two groups of patients before and after the treatment of serum ALT, AST, hyaluronic acid, laminin and type III collagen content. Results After treatment, the observation group serum ALT[（42.4±14.6）U/L vs（55.8±17.7）U/L], AST[（34.3±12.2）U/L vs（43.2±13.5）U/L], hyaluronic acid[（95.6±28.6）ng/m L vs（128.2±25.7）ng/m L], adhesion protein were lower than the control group[（102.6±21.4）ng/m L vs（125.3±24.6）ng/m L], the difference was statistically significant（P〈0.05）. Conclusion Compound Biejiaruangan tablets combined with entecavir can effectively improve liver function in patients with chronic hepatitis B and hepatic fibrosis, decrease the levels of cytokines related to hepatic fibrosis.